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Cirrhosis is a leading cause of death in the United States and
worldwide. Beta-blockers have been established in numerous
studies as part of the cornerstone of the medical management
of cirrhosis, particularly in the primary and secondary prevention
of variceal hemorrhage. However, new evidence has cautioned
the use of beta-blockers in patients with end-stage cirrhosis
and refractory ascites. In this article, we review the beneﬁcial
effects of beta-blocker therapy, the potential harms of aggressive
beta-blocker therapy, and provide suggestions regarding the
appropriate use of this class of medications in patients with
cirrhosis.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Cirrhosis is a leading cause of mortality in the United States and
worldwide [1,2]. Within the developed world, the leading causes
of cirrhosis include alcoholic liver disease, hepatitis C, and more
recently, non-alcoholic fatty liver disease (NAFLD) and non-alco-
holic steatohepatitis (NASH). Ever since NASH was described as a
cause for cryptogenic cirrhosis [3], there has been increasing rec-
ognition that NASH may become the most common cause of
advanced liver disease in the coming decades [4]. It is projected
that between 2015 and 2030, NASH cirrhosis will overtake hepa-
titis C cirrhosis as the most common indication for liver trans-
plantation in the United States [5]. Studies have also implicated
NASH risk factors including metabolic disease as being co-morbid
with chronic hepatitis C [6] and alcoholic liver disease [7]. Some
patients have all three insults to their liver.
Given the comorbidity of hypertension, metabolic syndrome,
and NASH cirrhosis, increasing numbers of patients with chronic
liver disease are now on antihypertensives for essential hyper-
tension. In a study of outpatient antihypertensive prescribingJournal of Hepatology 20
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essential hypertension increased 33% from 29.8 million visits in
1993 to 39.6 million visits in 2004 [8]. Beta-adrenergic antago-
nists (‘‘beta-blockers’’) have been established as part of the cor-
nerstone of the medical management of hypertension [9], as
well as acute coronary syndrome [10], and congestive heart fail-
ure [11].
Beta-blockers have also been well established in the preven-
tion of variceal hemorrhage in patients with cirrhosis [12–15].
The use of non-selective beta-blocker therapy in the secondary
prevention of variceal hemorrhage was ﬁrst introduced in 1981
[12]. Subsequent studies expanded the role of non-selective
beta-blockers to include primary prevention of variceal hemor-
rhage in patients with known cirrhosis and large esophageal
varices [13]. Beta-blocker therapy has been demonstrated to be
cost-effective [16–18], and may be also beneﬁcial in the preven-
tion of other complications of cirrhosis and portal hypertension,
including bleeding from portal hypertensive gastropathy
[19,20], and the development of spontaneous bacterial peritonitis
[21]. However, new studies have cautioned the use of beta-block-
ers in patients with decompensated cirrhosis [22,23]. Updated
recommendations are therefore needed regarding the appropri-
ate use of beta-blockers in patients with cirrhosis.Beta-blockers in cirrhosis
In its early stages, liver disease is often asymptomatic. As cirrho-
sis advances, portal hypertension develops, resulting in ascites,
hepatic encephalopathy, and variceal hemorrhage. Ascites is the
most common major complication of cirrhosis, occurring in 50%
of patients within ten years of diagnosis [24]. The presence of
ascites is an ominous landmark in the progression of cirrhosis,
as 15% of patients with ascites will succumb within 1 year, and
44% within 5 years [25]. Over one third of patients diagnosed
with cirrhosis develop esophageal varices within three years of
diagnosis [26].
Circulatory disturbances also develop, including increased
cardiac output and heart rate, decreased systemic vascular resis-
tance, and decreased mean arterial blood pressure. The most
widely accepted explanation of the hemodynamics in cirrhosis,
the peripheral arterial vasodilatation hypothesis [27], states that
systemic vasodilatation from reduced systemic vascular
resistance leads to arterial underﬁlling, which together with the
sequestration of ﬂuid into the peritoneal cavity, activates14 vol. 60 j 643–653
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salt-retaining mechanisms and neurohormonal systems such as
the sympathetic nervous system and the renin-angiotensin-aldo-
sterone system to counteract low arterial blood pressures [28]. As
a result, although plasma and blood volume is increased in
cirrhosis, patients with decompensated cirrhosis and ascites have
a decreased effective arterial blood volume [27–30]. Paracentesis
further induces arteriolar vasodilation and results in additional
decrease in effective arterial blood volume [31].
It is in this pathophysiological context that beta-adrenergic
blockade has both theoretical beneﬁts as well as adverse effects.
Non-selective beta-blockers such as propranolol and nadolol
achieve their effects through the dual mechanism of reducing
cardiac output via beta-1 adrenergic blockade, and reducing por-
tal blood ﬂow through splanchnic vasoconstriction via beta-2
adrenergic blockade [32]. Both mechanisms are clearly necessary
for these medications to be safe and effective in cirrhosis; selec-
tive beta-1 antagonists such as metoprolol and atenolol have
been shown to be less effective and are not recommended for
the prophylaxis of variceal hemorrhage [33,34].
Beneﬁts of beta-blocker therapy
The use of non-selective beta-blocker therapy was ﬁrst intro-
duced by Lebrec and colleagues in 1981 [12]. In their study, 74
patients presenting with a ﬁrst episode of variceal bleeding were
randomized to either placebo or oral propranolol targeted to a
25% reduction in heart rate. They found that 96% of patients in
the propranolol group were free of recurrent gastrointestinal
bleeding at one year, compared to 50% of patients in the placebo
group [12]. The ﬁndings from this and additional studies estab-
lished the role of non-selective beta-blockers in the secondary
prevention of gastrointestinal hemorrhage [35].
Subsequent studies expanded the role of non-selective beta-
blockers. Pascal and colleagues in 1987 studied the role of pro-
pranolol in the prevention of a ﬁrst upper gastrointestinal
bleeding event in patients with known cirrhosis [13]. In their
study, 230 patients with large esophageal varices without previ-
ous episodes of bleeding were randomized to either placebo or
propranolol targeted to a 20–25% reduction in heart rate. They
found that 74% of patients in the propranolol were free of vari-
ceal bleeding at one year, compared to 39% in the placebo group,
suggesting that propranolol has a role in decreasing the inci-
dence of the ﬁrst episode of upper gastrointestinal bleeding in
patients with cirrhosis [13]. Similarly, two year survival was
72% in the propranolol group, compared to 51% in the placebo
group, demonstrating a signiﬁcant survival beneﬁt in the use
of propranolol in patients with cirrhosis and large esophageal
varices [13]. A meta-analysis from Poynard and colleagues in
1991 analyzed four randomized clinical trials [13,36–38], and
determined that non-selective beta-blockers are effective in
preventing ﬁrst bleeding episode and reducing the mortality
rate from gastrointestinal bleeding among patients with cirrho-
sis [14]. Additional meta-analyses have since established the
use of non-selective beta-blockers as ﬁrst-line pharmacother-
apy in both primary and secondary prevention of variceal hem-
orrhage (Table 1) [15,39].
Adverse effects of beta-blocker therapy
Despite the proven clinical effectiveness of beta-blocker therapy,
its success is limited by potential adverse effects and suboptimal644 Journal of Hepatology 201treatment adherence. Studies in the cardiology literature have
shown that patient adherence to beta-blocker therapy following
myocardial infarction decline substantially over time [40]. Simi-
larly, studies in the hepatology literature have suggested that
despite well established guidelines and recommendations, as
few as 6–22% of patients with known medium or large varices
received primary prophylaxis with beta-blockers [41]. Side
effects led to treatment discontinuation in approximately 15%
of patients in the various beta-blocker trials in patients with cir-
rhosis [32].
Beta-blocker therapy can result in both cardiac as well as non-
cardiac adverse effects. The decrease in cardiac output from beta-
1 antagonism may cause major cardiac side effects. Despite the
central role of beta-blockers in the management of congestive
heart failure, beta-blockers may also exacerbate heart failure, or
even precipitate heart failure in patients with pre-existing car-
diac dysfunction and borderline compensation who are reliant
upon sympathetic drive [42]. Beta-blockers also signiﬁcantly
decrease chronotropy, depressing conduction through the atrio-
ventricular node. This can result in symptomatic bradycardia, or
even high grade heart block [43].
The acute withdrawal of beta-blocker therapy can lead to seri-
ous morbidity and potential mortality [44]. Abrupt cessation of
beta-blocker therapy can result in accelerated angina, myocardial
infarction, and sudden death, even in patients who do not previ-
ously have coronary artery disease [45,46]. These symptoms are
presumably due to rebound sympathetic activity resulting in a
hyperadrenergic state, which is more likely to occur with
shorter-acting medications such as propranolol [47].
Most of the major non-cardiac adverse effects of beta-blockers
result from the non-selective beta-adrenergic blockade. Non-
selective beta-blockers can result in increased airways resistance
in patients with bronchospasm, and therefore should be avoided
in patients with known bronchospastic diseases [48]. Nonselec-
tive beta-blockers can also cause exacerbations of peripheral
artery disease due to the reduction of cardiac output and block-
ade of beta-2-adrenergic skeletal muscle vasodilation, resulting
in local vascular insufﬁciency. Initial studies of patients with
peripheral artery disease taking propranolol showed complica-
tions of claudication, cold extremities, absent pulses, cyanosis,
and impending gangrene [49]. Additionally, in patients with dia-
betes mellitus, glucose recovery from insulin-induced hypoglyce-
mia is dependent on epinephrine-mediated beta-adrenergic
mechanisms, which can be dangerously impaired by the use of
non-selective beta-blockers such as propranolol [50]. Finally,
commonly reported side effects from beta-blockers also include
depression, fatigue, and sexual dysfunction [51]. It has been pre-
viously hypothesized that these symptoms are associated with
central nervous system effects of older generation lipophilic
beta-blockers such as propranolol, however a meta-analysis of
clinical trials showed no increased risk of depression and small
increases in fatigue and sexual dysfunction, without signiﬁcant
differences by the degree of beta-blocker lipid solubility [52].
Studies of beta-blockers in the cardiology literature have
almost uniformly suggested that side effects are decreased with
selective beta-1 antagonists. However, selective beta-1 antago-
nists such as metoprolol and atenolol have been shown to be less
effective in portal hypertension and are not recommended for the
prophylaxis of variceal hemorrhage [33,34]. Additional studies
focused on adverse effects of non-selective beta-blockers have
been generally lacking. It should be noted that adverse effects4 vol. 60 j 643–653
Table 1. Key studies supporting beta-blocker usage.
Ref No. Author Year Type of Trial Results p value Mortality p value
[12] Lebrec et al. 1981 Propranolol vs. placebo 
for secondary prevention 
of variceal bleeding
Free of recurrent GI bleeding 
Free of first variceal bleeding 
Free of first variceal bleeding 
Free of first variceal bleeding 
Free of first variceal bleeding 
ascites, free of first variceal
significant in subgroup of
96 vs. 50%
<0.0001 Not studied
[13] Pascal et al. 1987 Propranolol vs. placebo 
for primary prevention of 
variceal bleeding
74 vs. 39%
<0.05 Two year survival 
72 vs. 51%
<0.05
[36] Lebrec et al. 1988 Nadolol vs. placebo for 
primary prevention of 
variceal bleeding
97 vs. 77%, only statistically 
compliant patients
<0.02 Not studied
[37] Ideo et al. 1988 Nadolol vs. placebo for 
primary prevention of 
variceal bleeding
94 vs. 70%
<0.02
difference
No significant
[38] Italian 
multicenter 
project
1989 Propranolol vs. placebo 
for primary prevention of 
variceal bleeding
74 vs. 59%
n.s. 42 month survival
51 vs. 59%
n.s.
In subset of patients without 
bleeding in 83 vs. 61%
0.028 42 month survival 
65 vs. 66%
n.s.
n.s., not signiﬁcant.
JOURNAL OF HEPATOLOGYof beta-blockers have mostly been reported in the cardiology lit-
erature, rather than the hepatology literature. In clinical trials
and meta-analyses in the hepatology literature, beta-blockers
have not shown decreased survival, and have almost consistently
shown beneﬁt. It is therefore not clear whether the lack of
reported adverse effects are due to existing studies not having
been speciﬁcally designed to uncover adverse effects, the inabil-
ity to generalize results from the cardiology literature to patients
with cirrhosis, or other immeasurable factors such as patient
non-compliance or type II statistical error.
The differential effect of beta-blockers in cirrhosis
Recent studies suggest that beta-blockers may be effective only
within a particular clinical window of advanced liver diseaseTable 2. Key studies suggesting potential harm from beta-blocker usage.
Ref No. Author Year Type of trial
[53] Groszmann et al. 2005 Timolol vs. placebo for 
prevention of gastrointestinal 
varices
[58] Krag et al. 2010 CI and MAP in cirrhosis and 
ascites
[22] Serste et al. 2010 Propranolol in patients with 
cirrhosis and refractory ascites
[23] Serste et al. 2011 Propranolol and development of 
paracentesis-induced circulatory 
dysfunction
CI, cardiac index; MAP, mean arterial pressure.
Journal of Hepatology 201[26]. Outside of this window, beta-blockers may be ineffective
in early cirrhosis with some increase in adverse events, and
potentially harmful in advanced cirrhosis (Table 2 and Fig. 1).
In patients with early cirrhosis, the ineffectiveness of beta-
blocker therapy can be attributed to a milder splanchnic and sys-
temic hyperdynamic circulatory state [53]. This was suggested in
a large multicenter clinical trial from Groszmann and colleagues
in 2005, which showed the non-selective beta-blocker timolol to
be ineffective in preventing the development of varices in unse-
lected patients with cirrhosis and portal hypertension [53]. In
their study, 213 patients with cirrhosis and portal hypertension
conﬁrmed with hepatic venous pressure gradient (HVPG) mea-
surements were randomized to receive either placebo or timolol
targeted to a 25% reduction in heart rate or a goal heart rate of 55
beats per minute. At a median follow-up period of 54.9 months,gastrointestinal varices. Adverse events 18% in timolol group vs.
6% in placebo group (p = 0.006)
6 month survival 50% and 1 year survival <40% when
CI <1.5 L/min/m2
6 month survival >90% and 1 year survival >70% when 
CI >1.5 L/min/m2
6 month survival 60% and 1 year survival <40% when
MAP ≤80 mmHg
6 month survival >80% and 1 year survival >70% when 
MAP >80 mmHg
1 year survival 19% in patients treated with propranolol, 1 year 
survival 64% in patients not treated with propranolol (p <0.0001)
of paracentesis-induced circulatory dysfunction among patients 
given propranolol, decreased development of paracentesis-
induced circulatory dysfunction after discontinuation of 
propranolol
Major findings
No statistically significant difference in development of
Significant decrease in MAP after paracentesis with development
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Early cirrhosis Decompensated cirrhosis
(medium-large varices)
End-stage cirrhosis
(refractory ascites)
• Beta-blockers have no effect no
survival, may increase adverse
events
• Beta-blockers improve survival
by reducing variceal bleeding 
and gut bacterial translocation
• Beta-blockers reduce survival due to
negative impact on cardiac reserve, resulting
in decreased perfusion to vital organs
during periods of stress and precipitation of
hepatorenal syndrome
• May use beta-blocker for
cardiovascular indications
• Cardiac reserve intact • Cardiac reserve intact but
steadily declining
• Cardiac compensatory reserve critically
impaired, with baseline hypotension 
• SNS and RAAS activity at baseline • SNS and RAAS activity • SNS and RAAS maximally stimulated, can no
longer maintain adequate blood pressure
• Low risk of gut bacterial
translocation
• Increased risk of gut bacterial
translocation
• High risk of gut bacterial translocation
• Low risk of mortality • Increased risk of mortality • High risk of mortablity
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Fig. 1. The differential effect of beta-blockers in cirrhosis.Modiﬁed with permission from: Krag A, Wiest R, Albillos A, Gluud LL. The window hypothesis: haemodynamic
and non-haemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window in the disease. Gut 2012;61:967–969. Copyright  2012 BMJ
Group.
Reviewthe trial showed no signiﬁcant difference in the development of
gastrointestinal varices or variceal bleeding. However, the study
demonstrated a statistically signiﬁcant increase in the number
of adverse events (48% in the timolol group vs. 32% in the placebo
group), which included bradycardia, fatigue, shortness of breath,
syncope, claudication, and impotence. It was noted that drug
intolerance limited the ability to further up-titrate timolol dos-
ing, as patients were reluctant to tolerate its side effects. The
study concluded that the use of beta blockers cannot be widely
recommended because of the increased incidence of serious side
effects [53].
In advanced cirrhosis, a number of circulatory changes occur,
including the up-regulation of the sympathetic nervous system
[54,55] and of the renin-angiotensin-aldosterone system
[56,57]. These circulatory changes, along with the development
of sodium and water retention and the formation of ascites, are
aimed at maintaining adequate cardiac output and organ646 Journal of Hepatology 201perfusion. They reﬂect an adaptive response to the peripheral
vasodilation, effective hypovolemia, and arterial hypotension
that accompanies advanced cirrhosis. However, as cirrhosis pro-
gresses, the cardiovascular system eventually loses its compensa-
tory ability. It is at this stage that the maintenance of blood
pressure and cardiac output is paramount in prolonging overall
survival, and there is evidence that the hemodynamic effects of
beta-blockers in reducing blood pressure and cardiac output
may actually result in decreased survival in this subset of patients
[22,26,58].
Blood pressure and survival
The correlation between blood pressure and survival in patients
with cirrhosis was suggested by Llach and colleagues in 1988
[59]. In their survival analysis of 139 patients with cirrhosis
and ascites, mean arterial pressure was found to be an4 vol. 60 j 643–653
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independent predictor of survival [59]. Mean arterial pressure of
682 mmHg was the single variable most strongly correlated with
shortened survival; the survival probability rate of patients with
mean arterial pressure 682 mmHg was approximately 20% at
24 months and 0% at 48 months, in contrast with approximately
70% at 24 months and 50% at 48 months among patients with
mean arterial pressure >82 mmHg [59]. It was also observed that
patients with ascitic ﬂuid protein61 g/dl correlated with a signif-
icantly shorter survival, similar to previous observations that
patients with low ascitic ﬂuid protein levels are predisposed to
developing spontaneous bacterial peritonitis [60]. The study con-
cluded that the increased activity of the renin-angiotensin-aldo-
sterone and sympathetic nervous systems in patients with
cirrhosis with ascites is a homeostatic response to maintain arte-
rial pressures near or within normal range, and that mean arterial
pressure is possibly itself a reﬂection of the degree of alteration of
the splanchnic and portal circulation [59].
A hyperdynamic circulation with arterial underﬁlling from
splanchnic vasodilation also results in the development of hepa-
torenal syndrome, a major cause of mortality in patients with cir-
rhosis [61]. Krag and colleagues demonstrated that a low cardiac
output state predicts the development of hepatorenal syndrome
and subsequent survival in patients with cirrhosis and ascites
[58]. In their study of 24 patients with cirrhosis and ascites,
patients with a cardiac index below 1.5 L/min/m2 had signiﬁ-
cantly decreased survival compared to those with a cardiac index
above 1.5 L/min/m2 [58]. The study also showed that cumulative
survival in patients with mean arterial pressure below 80 mmHg
was 60% at 6 months and <40% at 12 months; in contrast, survival
in patients with mean arterial pressure above 80 mmHg was
>80% at 6 months and >70% at 12 months [58]. The study con-
cluded with a suggestion that in patients with low cardiac indices
and ascites, beta-blockers and/or other methods of decreasing
systemic pressures may worsen hemodynamics, resulting in the
development of hepatorenal syndrome and subsequent mortality
[58].
Midodrine
Additional evidence conﬁrming the importance of maintaining
cardiac output in patients with advanced cirrhosis has been sug-
gested among studies of midodrine, an alpha-1 adrenergic ago-
nist [62–66]. Angeli and colleagues in 1998 demonstrated that
midodrine has a preferential effect on the splanchnic circulation,
and its acute administration overall improves systemic hemody-
namics, renal function, and sodium excretion in non-azotemic
patients with ascites [62]. Their ﬁndings were followed by subse-
quent studies, which introduced the combination of octreotide
and midodrine as a treatment for type 1 hepatorenal syndrome
[67,68]. In a recent randomized controlled study from Singh
and colleagues, midodrine therapy was shown to result in a sig-
niﬁcant increase in urinary volume, urinary sodium excretion,
and mean arterial pressure; with decrease in plasma renin activ-
ity and in overall mortality [66]. The study concluded that mido-
drine improved systemic hemodynamics without causing renal
or hepatic dysfunction [66].
ACE inhibitors
Studies investigating the effects of angiotensin-converting
enzyme (ACE) inhibitors and angiotensin receptor blockersJournal of Hepatology 201(ARBs) in patients with cirrhosis have likewise shown that reduc-
ing cardiac index and mean arterial pressures results in worsened
outcomes in patients with advanced cirrhosis and ascites [69–
72]. The latest clinical practice guidelines from both the American
Association for the Study of Liver Diseases and the European
Association for the Study of the Liver on the management of adult
patients with ascites due to cirrhosis recommend against the use
of ACE inhibitors and ARBs in patients with ascites due to con-
cerns of hypotension and renal failure [73–75].
Carvedilol
Similarly, studies of newer-generation beta-blockers such as car-
vedilol concluded that while carvedilol has a potent portal hypo-
tensive effect that may be superior to propranolol, it has greater
potential to cause systemic hypotension, especially in patients
with cirrhosis and ascites [76–79]. Thus far, evidence supporting
the use of carvedilol for portal hypertension has been limited
[80]. In one study from Banares and colleagues, 35 patients were
randomized to carvedilol, propranolol, or placebo [77]. Carvedilol
was found to markedly reduce HVPG greater than propranolol;
patients receiving carvedilol achieved HVPG <12 mmHg or >20%
decrease from baseline HVPG in a greater proportion than pro-
pranolol (64% vs. 14%, p <0.05). However, carvedilol also caused
signiﬁcant arterial hypotension with average decrease in mean
arterial pressure of 17.2% in the carvedilol group vs. 3.4% in
the propranolol group [77]. In a follow-up study, 51 patients were
randomized to long-term carvedilol or propranolol [78]. Carvedi-
lol was shown to cause a greater decrease in HVPG than propran-
olol, with a greater proportion of patients achieving an HVPG
reduction of >20% or <12 mmHg. However, the study again
showed a signiﬁcant decrease in mean arterial pressure of
11% in the carvedilol group vs. 5% in the propranolol group.
Patients receiving carvedilol also had signiﬁcant increases in
plasma volume, body weight, and worsening of pre-existing asci-
tes [78].
More recently, Tripathi and colleagues compared carvedilol vs.
variceal band ligation in a randomized controlled trial of 152
patients with medium or large esophageal varices [79]. The car-
vedilol group was found to have lower rates of ﬁrst variceal
bleeding of 10% vs. 23% in the variceal band ligation group. There
were no signiﬁcant differences in overall mortality or bleeding-
related mortality. The study concluded that carvedilol is effective
for primary prophylaxis of variceal bleeding in patients with
high-risk esophageal varices [79]. Thus, while initial studies con-
cluded that the clinical applicability of carvedilol is limited by its
systemic hypotensive effects, more recent studies suggest a
potential role for carvedilol in the primary and secondary preven-
tion of variceal bleeding. However, the data at present is incon-
clusive at best and merits additional investigation.
Despite the central role of beta-blockers in the treatment of
hypertension, acute coronary syndrome, and congestive heart
failure, recent concerns have been raised by the cardiology com-
munity regarding the use of beta-blockers. Several studies have
suggested that no evidence existed that beta-blockers prevent
ﬁrst episodes of cardiovascular events in patients with hyperten-
sion, and in some trials, beta-blockers actually had worse out-
comes compared to other classes of antihypertensives [81]. One
meta-analysis concluded that beta-blockers were associated with
a higher risk of death from cardiovascular causes when compared
to renin-angiotensin blockade [82]. Newer guidelines no longer4 vol. 60 j 643–653 647
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recommend the use of beta-blockers in the initial treatment of
hypertension [83,84]. Furthermore, data from the POISE trial
studying the effects of perioperative metoprolol in patients
undergoing non-cardiac surgery found that although metoprolol
decreased the risk of myocardial infarction, cardiac revasculariza-
tion, and atrial ﬁbrillation, it also resulted in an excess risk of
death, stroke, and clinically signiﬁcant hypotension and brady-
cardia [85].Beta-blockers in refractory ascites
The challenges and adverse effects of beta-blockers appear to be
most pronounced in patients with advanced cirrhosis and refrac-
tory ascites. In 2010, almost 30 years following their landmark
article on the use of propranolol for the prevention of recurrent
variceal bleeding [12], Lebrec and colleagues (Serste et al.)
showed in a prospective observational study that the use of
beta-blockers in patients with refractory ascites may be associ-
ated with poor survival, suggesting that beta-blockers should
be contraindicated in this subclass of patients [22], Their study
included 151 patients with cirrhosis and refractory ascites, who
all regularly underwent large-volume paracentesis and intrave-
nous albumin administration. The overall mean survival was
10 months, with a 41% probability of survival at 1 year. However,
the median survival was dramatically lower in patients treated
with propranolol (5 months, with 19% probability of survival at
1 year), as compared to the median survival in patients who were
not treated with propranolol (20 months, with 64% probability of
survival at 1 year) [22]. This four-fold decrease in median survival
with the administration of propranolol in patients with refractory
ascites was highly statistically signiﬁcant [22]. In their editorial
regarding this study, Wong and Salerno stated that although
there were methodological concerns to the study, an important
question was raised as to the safety of propranolol in patients
with cirrhosis and refractory ascites [86].
A subsequent self-controlled cross-over study by Lebrec and
colleagues (Serste et al.) showed that beta-blockers are associated
with the development of paracentesis-induced circulatory dys-
function, further suggesting that beta-blockers are correlated
with poor survival in this group of patients [23]. In this study
involving 10 patients in a cross-over design, patients given
propranolol experienced a signiﬁcant decrease in mean arterial
pressure with no signiﬁcant change in heart rate following
paracentesis, with the development of paracentesis-inducedTable 3. Beta-blocker dosing-regimens.
Ref No. Author Year Type of trial
[12] Lebrec et al. 1981 Propranolol vs. placebo for sec
prevention of variceal bleeding
[13] Pascal et al. 1987 Propranolol vs. placebo for prim
prevention of variceal bleeding
[36] Lebrec et al. 1988 Nadolol vs. placebo for primary
prevention of variceal bleeding
[37] Ideo et al. 1988 Nadolol vs. placebo for primary
prevention of variceal bleeding
[38] Italian multicenter 
project
1989 Propranolol vs. placebo for prim
prevention of variceal bleeding
648 Journal of Hepatology 201circulatory dysfunction in eight of the ten patients [23]. After dis-
continuation of beta-blockers, patients experienced a signiﬁcant
increase in heart rate with no signiﬁcant change in mean arterial
pressure following paracentesis, with the development of para-
centesis-induced circulatory dysfunction in only one of the ten
patients. The study concluded that among patients with cirrhosis
and refractory ascites, beta-blockers may be associated with an
increased risk of paracentesis-induced circulatory dysfunction,
which although may be clinically silent in itself, is associated
with shortened survival [87].
One important observation mentioned by Lebrec and col-
leagues in their recent study [22] is that the effects of beta-block-
ers in the subset of patients with cirrhosis and refractory ascites
had actually never been studied. Even the original studies, which
demonstrated a clear and convincing survival advantage of beta-
blockers in patients with cirrhosis and esophageal varices,
excluded the subset of patients with refractory ascites. One of
the speciﬁc inclusion criteria in the original study by Lebrec
and colleagues in 1981 was that ‘‘ascites was absent or mild and
transient’’ [12]. In the study by Pascal and colleagues in 1987,
patients were included only if they had a Child-Pugh score of less
than 14 [13]. In the meta-analysis from Poynard and colleagues in
1991 of four trials of beta-blockers in the primary prevention of
esophageal variceal bleeding, advanced cirrhosis and the pres-
ence of ascites were independently associated with death in both
patients receiving propranolol and not receiving propranolol [14].
However, patients with refractory ascites were again excluded
from any of the trials used in the meta-analysis [14]. Certainly
additional research is needed to fully study the effects of beta-
blockers in this population; however, based on the available evi-
dence, it is likely that such studies will show a detrimental effect
of beta-blockers in patients with advanced cirrhosis and refrac-
tory ascites.
At present, due to the paucity of available studies, we have
determined that although recent studies are suggesting harm in
the use of beta-blockers in patients with advanced cirrhosis and
refractory ascites, there exists insufﬁcient evidence to draw
deﬁnitive conclusions. The existing studies do not share enough
homogeneity for pooled analysis or meta-analysis to be reliably
and conﬁdently performed. Additional studies to evaluate the
role and safety of beta-blockers in patients with advanced cirrho-
sis and refractory ascites are critically needed; however develop-
ing a large randomized controlled trial to answer aspects of this
question is certain to be difﬁcult especially as beta-blockers are
increasingly becoming generic.Dosing regimen
ondary Propranolol titrated to reduce resting heart rate by 25%, 
dose ranged from 20-180 mg given twice daily
ary Propranolol titrated to reduce resting heart rate by 20-
25%, starting dose 20 mg given twice daily, increased 
as required to maximum dose of 160-320 mg long-acting 
propranolol given once daily
 Nadolol titrated to reduce resting heart rate by 25%, 
starting dose 80-160 mg given once daily
 Nadolol given at dose from 40-120 mg once daily
ary Propranolol titrated to reduce resting heart rate by 25%, 
dose ranged from 10-480 mg daily
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Additional challenges affecting beta-blocker therapy
There are several additional challenges to beta-blocker therapy in
cirrhosis. First, the appropriate dosing of beta-blockers in cirrho-
sis can be problematic and demands further investigation. The
current propranolol dosing regimen was established by several
of the early non-selective beta-blocker clinical trials (Table 3),
without explanation to the origin or scientiﬁc validity of such a
dosing regimen. Lebrec’s original study called for propranolol to
be given at increasing doses until the heart rate was reduced
by approximately 25%, with doses ranging from 20 to 180 mg
given twice a day [12]. Subsequent clinical studies evaluating
the hemodynamic effects of propranolol continued to utilize this
dosing regimen [88–90]. Additional investigations regarding the
dosing of beta-blockers have since escaped scientiﬁc study.
A number of the beta-blocker trials determined that a
decrease in portal pressure during chronic treatment, as mea-
sured by a decrease in the hepatic venous pressure gradient
(HVPG) to <12 mmHg or by >20% from baseline, was a strong pre-
dictor of clinical effectiveness [19,91]. Studies have shown that
assessment of hemodynamic response with the HVPG may be
the best predictor of clinical efﬁcacy in patients being treated
with beta-blockers [53,92]. However, dosing to HVPG goals is
problematic as this method is invasive, impractical, and not rou-
tinely performed in most institutions in the United States except
in clinical research studies [93].
Second, previous studies have implicated patients’ unwilling-
ness to tolerate the side effects of beta-blockers as a factor in
treatment failure [53]. Regardless of whether or not the side
effects have been conﬁrmed in rigorous meta-analyses, in our
anecdotal experience patients routinely complain of side effects
including fatigue, lightheadedness, and erectile dysfunction, and
many unilaterally discontinue or dose-reduce the medication
without reporting this to their physician [94]. It is therefore notTable 4. Summary of recommendations for beta-adrenergic antagonists in patients
Clinical situation Recommendation for beta-b
Early cirrhosis 
Without medium-large esophageal 
varices
Not indicated for cirrhosis, h
Compensated cirrhosis
With medium-large esophageal varices
systemic hypotension.
Decompensated cirrhosis
Initial episode of variceal bleeding Indicated to prevent recurre
hypotension. 
With sepsis or hepatorenal syndrome Discontinue existing beta-bl
End-stage cirrhosis
With refractory ascites Not indicated due to decrea
Existing beta-blockers shou
treatment modality such as 
pressure.
Other clinical scenarios
Patients with poor compliance or 
inadequate follow-up care
medical compliance
Adjust beta-blockers based 
reduction in baseline heart r
side effects tolerate. Home 
clinic measurement.
Routine office visit for patient with good
Not indicated as risks of cau
Indicated to prevent first epi
(e.g. coronary artery diseas
Journal of Hepatology 201surprising that an increasing amount of evidence suggests that
many patients fail to receive evidence-proven treatments [41,95].
Third, the limited therapeutic window during which beta-
blockers provide a survival beneﬁt demands close follow-up to
minimize the risk of causing harm to the patient, and to ensure
that beta-blockers are discontinued when the patient’s disease
progresses beyond this window. In our experience, we
increasingly encounter patients with cirrhosis on multiple anti-
hypertensives who invariably develop azotemia, hypotension,
and end-organ damage as their cirrhosis progresses. Beta-
blockers should not be recommended to patients who have poor
follow-up or who have issues with non-compliance; the initiation
and continuation of beta-blockers demands meticulous follow-
up, ideally with home monitoring of blood pressure by patients
and frequent clinic visits with the physician. The hemodynamic
effects of these medications are signiﬁcant and may become dan-
gerous as these patients develop worsening cirrhosis.
Fourth, discontinuity of care is an increasingly challenging
issue in modern medicine. The widely popular hospitalist move-
ment has separated the outpatient physician from the inpatient
physician, creating discontinuity at a critical juncture in patient
care. Patients may be started on beta-blockers during their initial
hospitalization for a life-threatening variceal bleeding event, only
to be left in an ‘‘autopilot’’ state upon discharge. They may either
subsequently present to an emergency department months later
with systemic hypotension and azotemia, potentially at a differ-
ent hospital which has no records for the patient, or may develop
symptoms or side effects and unilaterally discontinue their med-
ication. This concern is supported by a recent study, which
showed that the increasing involvement of hospitalists was asso-
ciated with a signiﬁcant decrease in continuity of care [96].
Recent studies aimed at care coordination may help to decrease
the discontinuity of care and improve outpatient follow-up and
medication compliance [97].with cirrhosis.
lockers
owever may be indicated for concurrent cardiovascular disease 
nt variceal bleeding. Caution should be taken to avoid systemic 
ockers.
sed cardiac output and risk for hypotension and renal failure. 
ld be tapered and then discontinued. Consider alternative 
endoscopic band ligation. Consider midodrine to increase blood 
on serial blood pressure measurements over time. Titrate to 25% 
ate, or goal heart rate 55 beats/minute, as blood pressure and 
monitoring of pulse and blood pressure is superior to a single 
sing harm may substantially outweigh potential benefits.
sode of variceal bleeding. Caution should be taken to avoid 
e, congestive heart failure, atrial fibrillation, etc.).
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Recommendations and conclusions
One of the few beneﬁts of advanced cirrhosis may be that cirrho-
sis effectively cures hypertension. The emerging prevalence of
NAFLD and NASH cirrhosis, our society’s ongoing struggles with
metabolic syndrome and its comorbid diabetes mellitus and
essential hypertension, and the changing healthcare environment
in the United States draws new implications regarding the use of
beta-blocker therapy in patients with cirrhosis. Our overall rec-
ommendations for the use of beta-blockers are summarized in
Table 4 and Fig. 2.
Perhaps the most appropriate timing for beta-blocker therapy
was outlined in a recent hypothesis from Krag and colleagues
known as the ‘‘window hypothesis’’ (Fig. 1), which suggests that
beta-blockers improve survival only in a narrow clinical window
in the course of cirrhosis [26]. In early cirrhosis, beta-blockersOther indication for 
beta-blocker 
(i.e. hypertension, heart fa
coronary artery diseas
Consider alternative the
• Midodrine
• Endoscopic band li
Small va
Medium-large v
Variceal bleeding
Sepsis
Hepatorenal syndrom
Refractory ascites
Ascites Screenin
Compliant patient, 
good medical follow-up
Early cirrhosis
Compensated cirrhosis
Decompensated cirrhosis
End-stage cirrhosis
*When possible, beta-blockers should be tapered prior to being discon
Fig. 2. Algorithmic approach for beta-adrenergic antagonists in patients with cirrho
650 Journal of Hepatology 201have no effect on survival, increase adverse events and do not
prevent the formation of varices [53]. In this early stage, the ini-
tiation of beta-blockers is not recommended for the purpose of
preventing gastrointestinal bleeding, although they may be indi-
cated for cardiac comorbidities such as coronary artery disease
and congestive heart failure.
As portal pressures increase and the sympathetic nervous sys-
tem becomes increasingly activated, medium to large esophageal
varices develop, and there is increased risk of variceal bleeding
and bacterial translocation from the gut [98]. Ascites also begins
to develop at this stage. From a cardiovascular perspective, sys-
temic hemodynamics is still relatively preserved, cardiovascular
reserve is intact, and blood pressure and cardiac output are main-
tained to deliver adequate end-organ perfusion. In this middle
stage of cirrhosis, beta-blockers have been shown in numerous
trials to have survival beneﬁt [12,14,15,26]. Beta-blockers areStart cardioselective
beta-blocker
(i.e. metoprolol or 
carvedilol)
Assess for
progression of cirrhosis
Assess for
progression of cirrhosis,
monitor BP closely, 
continuously assess 
risks vs. benefits
Start non-selective
beta-blocker
(i.e. propranolol or nadolol)
ilure,
e)
rapies:
gation
rices
arices
e
g EGD
Non-compliant patient, 
poor medical follow-up
tinued
STOP
beta-blocker*
sis. BP, blood pressure; EGD, esophagogastroduodenoscopy.
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therefore indicated and recommended for the primary and sec-
ondary prevention of gastrointestinal bleeding, although they
should be promptly discontinued in the setting of either sepsis
or hepatorenal syndrome.
However, as cirrhosis progresses and cardiovascular reserve
becomes impaired, the sympathetic nervous system is maximally
stimulated to maintain cardiac output and end-organ perfusion.
Additional complications such as cirrhotic cardiomyopathy may
also develop [99]. In this advanced stage of cirrhosis, generally
reﬂected by refractory ascites, the evidence now suggests that
beta-blockers reduce survival. The inability of the circulatory sys-
tem to increase cardiac output via the beta-adrenergic systemdur-
ing situations of increased physiological stress results in decreased
mean arterial pressures, decreasedperfusion to vital organs, azote-
mia, and subsequent increased risk for hepatorenal syndrome and
end-organ damage [22,23,26,58]. In this ﬁnal stage of decompen-
sated cirrhosis, beta-blockers should neither be recommended
nor initiated. Additionally, beta-blockers should be tapered and
discontinued in those patients who develop refractory ascites,
worsening hypotension, or worsening azotemia [73,74]. Endo-
scopic band ligation of varices can be considered as a substitute
treatment to prevent variceal hemorrhage [13,100]. Consideration
should also be given to agents such asmidodrine that increase car-
diac output and blood pressure [62]. One potential option in
patients with end-stage cirrhosis that merits additional investiga-
tion would be to consider simultaneously using non-selective
beta-blockers for the prevention of variceal bleeding, and mido-
drine to improve systemic hemodynamics.
Many questions remain with regards to the exact therapeutic
parameters of beta-blockers in patients with cirrhosis, and addi-
tional studies on the optimal timing and dosage of beta-blockers
are certainly needed. An increasing amount of evidence supports
the limited use of beta-blockers in only a certain subset of
patients with cirrhosis. Outside this limited window of clinical
opportunity, the global harm of beta-blockers may ultimately
exceed its global beneﬁt.
Key Points
• Beta-adrenergic antagonists (“beta-blockers”) are
part of the cornerstone of the medical management
of cirrhosis, particularly in the primary and secondary
prevention of variceal hemorrhage
• New evidence cautions using beta-blockers in patients
with end-stage cirrhosis, and supports their use only in
a certain subset of patients with cirrhosis
• Beta-blockers are not indicated to prevent development
of varices in early cirrhosis
• Beta-blockers should be tapered and discontinued
when patients develop end-stage cirrhosis with
refractory ascites, as decreased cardiac output results
in decreased renal perfusion, azotemia, and increased
risk for hepatorenal syndrome and mortality
• Beta-blockers should not be initiated in patients with
poor medical follow-up or poor medical compliance,
as the limited therapeutic window during which beta-
blockers provide a survival benefit demands close
follow-upJournal of Hepatology 201Conﬂict of interestThe authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
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